Aclaris Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Aclaris Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Aclaris Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
Investors are testing whether Aclaris Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Aclaris Therapeutics, Inc. enters underwriting agreement for offering of 7,785,714 shares of common stock and 6,500,000 pre-funded warrants
Investors are testing whether Aclaris Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
The story matters when it changes Aclaris Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight
The development tests whether Aclaris Therapeutics, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Aclaris Therapeutics, Inc. Added to Russell 3000 and Russell 2000 Indexes Following 2025 Annual Reconstitution
The story matters when it changes Aclaris Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript
Investors are testing whether Aclaris Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest ACRS filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Aclaris Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →